Please provide your email address to receive an email when new articles are posted on . This installment of Pipeline Pulse focuses on a single cardiovascular risk ...

The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RE™ initiative to engage key U.S. healthcare ...

All sex, race, and risk category groups appeared to be affected by the heart disease risk posed by elevated lipoprotein(a), or Lp(a), according to pooled analysis of primary prevention studies.

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...

Lipoprotein (a) is a fatty particle that circulates in the blood and deposits cholesterol in the arteries contributing to ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Millions of Americans are born genetically predisposed to extremely high levels of a type of cholesterol that cause deadly heart attacks and strokes by middle age, yet they are almost always unaware ...

How lipoprotein(a) (Lp[a]) affects cardiovascular (CV) risk, particularly in the context of major adverse CV events (MACE) among patients based on the baseline atherosclerotic CV disease (ASCVD) ...